NCT05712265View on ClinicalTrials.gov

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 24, 2023

Primary Completion Date

February 23, 2023

Study Completion Date

February 23, 2023

Conditions
Antipsychotic Induced Weight GainNon-alcoholic Steatohepatitis (NASH)
Interventions
DRUG

Miricorilant

Miricorilant 6 x 100 mg coated tablets

DRUG

Fluvoxamine

Fluvoxamine 50 mg tablet

Trial Locations (1)

33126

Site 01, Miami

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY